Stearoylcarnitine

Name: Stearoylcarnitine
Brand: MedChemExpress
SKU: HY-113202
Rating: 4.5 (1 reviews)

Cat. No.: HY-113202 Purity: 99.80%: FAQs
Data Sheet
SDS

COA
Handling Instructions Technical Support

Stearoylcarnitine, a fatty ester lipid molecule, is an endogenous metabolite. Stearoylcarnitine can be used as PKC inhibitor. Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoylcarnitine inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoylcarnitine acts as a metabolomics biomarker for Parkinson’s disease. Stearoylcarnitine is a less potent inhibitor of GlyT2.

For research use only. We do not sell to patients.

Stearoylcarnitine Chemical Structure

CAS No. : 25597-09-5

Size	Stock	Quantity
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Stearoylcarnitine:

DL-Stearoylcarnitine Get quote
Stearoyl-L-carnitine-d₃ Get quote
Stearoyl-L-carnitine-d₉ chloride Get quote
Stearoyl-L-carnitine chloride Get quote

1 Publications Citing Use of MCE Stearoylcarnitine

•SSRN. 2023 Dec 20.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PKC Isoform Specific Products:

View All Isoforms

PKC PKCα PKCβ PKCγ PKCδ PKCε PKCη PKCζ PKCθ PKCμ PKC-ι ℩ PKCι

View All GlyT Isoform Specific Products:

View All Isoforms

GlyT1 GlyT2

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Human Endogenous Metabolite

In Vitro

Stearoylcarnitine (100 μM, 2 h) impairs mitochondrial energy metabolism in MIN6 cells^[1].
Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency via excessive β-oxidation and depletion of tricarboxylic acid (TCA) cycle and oxidative phosphorylation metabolites in type 2 diabetes (T2D) mouse pancreatic tissues^[1].
Stearoylcarnitine (1 μM, 25 min) significantly abolishes the stimulatory effect of triterpene derivative on ⁴⁵Ca²⁺ influx in pancreatic islets of male Wistar rats^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Stearoylcarnitine increases in the cortex, striatum/thalamus, and cerebellum in CD1 mouse pups (postnatal day 9) with hypoxic-ischemic brain injury (HIBI) induced by carotid artery ligation^[2].
Stearoylcarnitine (500 μM, 0-40 min) shows inhibitory towards lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma, but not in human plasma^[3].
Stearoylcarnitine is characterized as one of potential biomarkers involved in the pathogenesis of Parkinson’s disease (PD) ^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

427.66

Formula

C₂₅H₄₉NO₄

CAS No.

25597-09-5

Appearance

Solid

Color

White to off-white

SMILES

CCCCCCCCCCCCCCCCCC(O[C@H](CC([O-])=O)C[N+](C)(C)C)=O

Structure Classification

Ketones, Aldehydes, Acids

Initial Source

Microorganisms

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 7.14 mg/mL (16.70 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3383 mL	11.6915 mL	23.3831 mL
5 mM	0.4677 mL	2.3383 mL	4.6766 mL
10 mM	0.2338 mL	1.1692 mL	2.3383 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.85 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.85 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.85 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.80%

Select Batch:

Data Sheet (271 KB) SDS (252 KB)

COA (240 KB) HNMR (396 KB) RP-HPLC (164 KB) MS (68 KB)

Handling Instructions (2659 KB)

References

[1]. Aichler M, et al. N-acyl Taurines and Acylcarnitines Cause an Imbalance in Insulin Synthesis and Secretion Provoking β Cell Dysfunction in Type 2 Diabetes. Cell Metab. 2017 Jun 6;25(6):1334-1347.e4. [Content Brief]

[2]. Dave AM, et al. Neonatal Hypoxic-Ischemic Brain Injury Alters Brain Acylcarnitine Levels in a Mouse Model. Metabolites. 2022 May 22;12(5):467. [Content Brief]

[3]. Bell FP. Carnitine esters: novel inhibitors of plasma lecithin: cholesterol acyltransferase in experimental animals but not in man (Homo sapiens). Int J Biochem. 1983;15(2):133-6. [Content Brief]

[4]. Li XZ, et al. Cerebral metabonomics study on Parkinson's disease mice treated with extract of Acanthopanax senticosus harms. Phytomedicine. 2013 Oct 15;20(13):1219-29. [Content Brief]

[5]. da Luz G, et al. Triterpene derivative: A potential signaling pathway for the fern-9(11)-ene-2α,3β-diol on insulin secretion in pancreatic islet. Life Sci. 2016 Jun 1;154:58-65. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.3383 mL	11.6915 mL	23.3831 mL	58.4577 mL
	5 mM	0.4677 mL	2.3383 mL	4.6766 mL	11.6915 mL
	10 mM	0.2338 mL	1.1692 mL	2.3383 mL	5.8458 mL
	15 mM	0.1559 mL	0.7794 mL	1.5589 mL	3.8972 mL